AstraZeneca PLC (AZN)

26.01
NYSE : Health Care
Prev Close 26.01
Day Low/High 0.00 / 0.00
52 Wk Low/High 25.68 / 35.04
Avg Volume 6.35M
Exchange NYSE
Shares Outstanding 2.53B
Market Cap 65.32B
EPS 1.10
P/E Ratio 11.58
Div & Yield 0.90 (3.50%)

Latest News

Early Data Demonstrate Clinical Activity Of Acalabrutinib In Difficult-to-Treat Chronic Lymphocytic Leukemia

Early Data Demonstrate Clinical Activity Of Acalabrutinib In Difficult-to-Treat Chronic Lymphocytic Leukemia

AstraZeneca and its hematology Center of Excellence, Acerta Pharma, today announced preliminary results from the Phase I/II ACE-CL-001 clinical trial of acalabrutinib in subsets of patients with two difficult-to-treat...

Stocks Mixed as Crude Rally Boosts Energy Shares

Stocks Mixed as Crude Rally Boosts Energy Shares

Stocks turn mixed Wednesday as a rally in crude oil fails to provide an across-the-board lift.

Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield

Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Is This the Pullback I Ordered?

This could be cause for celebration.

AstraZeneca Announces Study Results Show SYMBICORT Improves Lung Function In Pediatric Asthma Patients

AstraZeneca Announces Study Results Show SYMBICORT Improves Lung Function In Pediatric Asthma Patients

Results from the international, multicenter Child Hood Asthma Safety and Efficacy (CHASE) 3 Phase III study showed that SYMBICORT ® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol 80/4.

Here's Which Pharma Giants Might Want to Buy Pfizer's Consumer Health Unit

Here's Which Pharma Giants Might Want to Buy Pfizer's Consumer Health Unit

A sale or spinoff of this business will likely get the attention of competitors that want to increase their over-the-counter product units.

European Stocks Close Lower as 'Trump Rally' Takes a Breather

European Stocks Close Lower as 'Trump Rally' Takes a Breather

European bond markets hit hard as traders brace for inflation rise, blunting two-day 'Trump rally'.

European Markets Higher As Global 'Trump Rally' Continues

European Markets Higher As Global 'Trump Rally' Continues

European stocks are trading higher Thursday, after massive gains in Japan, but government bond yields are also rising fast.

AstraZeneca Stocks Slips as Third-Quarter Crestor Sales, Earnings Disappoint

AstraZeneca Stocks Slips as Third-Quarter Crestor Sales, Earnings Disappoint

AstraZeneca saw a 44% decline in Crestor sales as generic brands challenge the company's cholesterol blockbuster.

5 Things You Must Know Before the Market Opens Thursday

5 Things You Must Know Before the Market Opens Thursday

U.S. stock futures rise and the Dow is poised to open at a record Thursday as equities continue their rally following Donald Trump's win in the U.S. presidential election.

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

Stock futures are tumbling Wednesday but are well off their lows as Republican Donald Trump is elected the next president of the United States in a surprising victory.

European Drug Companies Get an Injection From Trump Victory

European Drug Companies Get an Injection From Trump Victory

The threat of a government clampdown on drug prices is off the table with Clinton's defeat, while wider support for defensive stocks helped push pharmaceuticals higher.

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.

SBUX, AAPL, FB: Jim Cramer's Views

SBUX, AAPL, FB: Jim Cramer's Views

Cramer shares his views on the rise of the stay-at-home consumer. Starbucks, Apple and Facebook are among the stocks discussed.

What to Watch This Week: Presidential Election, Mylan Earnings

What to Watch This Week: Presidential Election, Mylan Earnings

For the week of November 7, all eyes will be on Tuesday's presidential election.

Alexion Soars, Then Falls Amid Takeover Rumors

Alexion Soars, Then Falls Amid Takeover Rumors

The biotech company cancelled its conference appearance and took its time filing its Form 10-Q with the Securities and Exchange Commission.

Cramer: Don't Just Stand There Like Bambi; Sell Some

Cramer: Don't Just Stand There Like Bambi; Sell Some

Stocks in the health care sector seem to have no underpinnings whatsoever.

New Data Shows Frequent ICU Admissions From Severe RSV Disease Among Preterm Infants In The First Three Months Of Life

New Data Shows Frequent ICU Admissions From Severe RSV Disease Among Preterm Infants In The First Three Months Of Life

AstraZeneca today announced data from the second season of its SENTINEL1 study, the largest study ever to examine laboratory-confirmed respiratory syncytial virus hospitalizations (RSVH) among US preterm infants 29-35 weeks...

Jim Cramer: AstraZeneca Is Reinventing Itself in Anti-Cancer

Jim Cramer: AstraZeneca Is Reinventing Itself in Anti-Cancer

Jim Cramer comments on AstraZeneca's recent success in a cancer drug trial.

AstraZeneca Is Now a Competitive Threat to Tesaro in Ovarian Cancer Maintenance Therapy

AstraZeneca Is Now a Competitive Threat to Tesaro in Ovarian Cancer Maintenance Therapy

AstraZeneca's Lynparza significantly delayed the recurrence of tumors in patients with ovarian cancer compared to a placebo, according to results from a phase III study announced by the company Wednesday.

LYNPARZATM (olaparib) Phase III SOLO-2 Trial Shows Significant Progression-Free Survival Benefit

LYNPARZATM (olaparib) Phase III SOLO-2 Trial Shows Significant Progression-Free Survival Benefit

AstraZeneca today announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LYNPARZA TM (olaparib) tablets (300mg twice daily) as a monotherapy for the maintenance treatment of...

Analysts' Actions -- Ameriprise, ConAgra, Domino's, Lear and More

Analysts' Actions -- Ameriprise, ConAgra, Domino's, Lear and More

Here are Friday's top research calls, including upgrades for ConAgra Foods and Domino's Pizza, and downgrades for Ameriprise and Lear.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: DNKN, TCP Downgrades: AZN Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Even High-Flying Tesaro and Its Ovarian Cancer Drug Has a Bear Thesis. Here It Is, Explained

Even High-Flying Tesaro and Its Ovarian Cancer Drug Has a Bear Thesis. Here It Is, Explained

Tesaro is soaring, but the company is overvalued if regulators decide to grant marketing clearance for niraparib only in a smaller, more restricted population of ovarian cancer patients.

Fulvestrant Demonstrates Progression-Free Survival Advantage In 1st Line Advanced Breast Cancer

Fulvestrant Demonstrates Progression-Free Survival Advantage In 1st Line Advanced Breast Cancer

AstraZeneca today announced data from the Phase III FALCON trial demonstrating superior median progression-free survival (PFS) for fulvestrant 500mg compared to anastrozole 1mg in the 1st line treatment of postmenopausal...

Clovis Falls on Fears Ovarian Cancer Drug Inferior to Competition

Clovis Falls on Fears Ovarian Cancer Drug Inferior to Competition

Takeover speculation that had fueled the recent rise in Clovis' stock price looks to be subsiding.

Chi-Med Not Your Typical 'Binary Biotech' Says CEO

Chi-Med Not Your Typical 'Binary Biotech' Says CEO

Chi-Med may be pressing ahead with a series of late-stage oncology drug trials, but it is anything but a one-trick pony biotech company.